In addition, other clinical trials to treat fibrosis through inhibiting inflammation are also explored, including anti-CCR2/CCR5 (NCT02217475, NCT03028740, NCT03059446, and NCT02330549) for liver fibrosis and non-alcoholic steatohepatitis, anti-IL-1 (NCT01538719) for systemic sclerosis, anti-IL-6 (NCT02453256) for scleroderma, and anti-CCL2 (NCT00786201) for pulmonary fibrosis. Here, CCR5 is linked to systemic sclerosis.